Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate
Name
NBT-RA38120B_Manalis_ed_NIHMS.pdf
Size
4.74 MB
Format
Adobe PDF
Checksum (MD5)
5791298b3f6eeeaef66ff8c0dabb7c35
Author(s)
Maire, Cecile L
Murakami, Mark A
Knoff, David S
Liu, Huiyun
Idbaih, Ahmed
Weinstock, David M
Ligon, Keith L
Stevens, Mark M.
Chou, Shijie Nigel
Kikuchi, Yuki
Date Issued
October 2016
Journal
Nature Biotechnology
Publisher
Nature Publishing Group
Citation
Stevens, Mark M; Maire, Cecile L; Chou, Nigel; Murakami, Mark A; Knoff, David S; Kikuchi, Yuki; Kimmerling, Robert J, et al. “Drug Sensitivity of Single Cancer Cells Is Predicted by Changes in Mass Accumulation Rate.” Nature Biotechnology 34, no. 11 (October 2016): 1161–1167.
Version
Author's final manuscript
Abstract
Assays that can determine the response of tumor cells to cancer therapeutics could greatly aid the selection of drug regimens for individual patients. However, the utility of current functional assays is limited, and predictive genetic biomarkers are available for only a small fraction of cancer therapies. We found that the single-cell mass accumulation rate (MAR), profiled over many hours with a suspended microchannel resonator, accurately defined the drug sensitivity or resistance of glioblastoma and B-cell acute lymphocytic leukemia cells. MAR revealed heterogeneity in drug sensitivity not only between different tumors, but also within individual tumors and tumor-derived cell lines. MAR measurement predicted drug response using samples as small as 25 μl of peripheral blood while maintaining cell viability and compatibility with downstream characterization. MAR measurement is a promising approach for directly assaying single-cell therapeutic responses and for identifying cellular subpopulations with phenotypic resistance in heterogeneous tumors.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Biology
Massachusetts Institute of Technology. Microsystems Technology Laboratories
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/nbt.3697
